Why Is NEKTAR THERAPEUTICS (NKTR) Stock Down Today?

NKTR stock fell 19.60% to $48.68 in a volatile session driven by the release of mid-stage trial data for its hair loss candidate, rezpegaldesleukin. The data, presented at a dermatology conference, triggered mixed reactions among analysts and investors. While some firms highlighted potential long-term benefits, the market reacted negatively, with the stock dropping sharply after midday.

What Happened

Nektar Therapeutics released new data from its Phase 2b trials for rezpegaldesleukin at the European Academy of Dermatology and Venereology. The stock initially opened with a small 0.7% gap up at $60.97 but quickly reversed course. By midday, it had fallen to a session low of $46.92. The data was met with skepticism from some analysts, including Jefferies, who called the selloff "unwarranted." Meanwhile, William Blair expressed optimism about the rezpeg data, and BTIG reiterated a Buy rating with a $178 price target. Despite these positive signals, the broader market interpreted the data as underwhelming, leading to a steep decline.

What The Data Shows

The stock has lost 25.6% over the past eight sessions, moving from $66.41 to $49.41. Intraday volume reached 3.4 million shares, three times the 3-month average, highlighting the intensity of the move. Insiders, including CEO Robin Howard and Chief R&D Officer Jonathan Zalevsky, sold shares on August 18, 2026. The 52-week tape also marked 15 fresh 52-week lows on October 1, 2026, underscoring the stock’s deteriorating trend. The company remains unprofitable, with a trailing 12-month net margin of -287.8% and a beta of 1.15.

What To Watch

Nektar Therapeutics does not have an upcoming earnings date listed, but coverage breadth and analyst commentary will be key to monitor in the coming days.